Intravenous Laser Blood Irradiation (ILBI) in Stroke Rehabilitation: Current Evidence and Clinical Applications

Stroke remains one of the leading causes of death and long-term disability worldwide. Even after successful acute treatment, many patients continue to experience neurological deficits, impaired mobility, chronic fatigue, pain, cognitive difficulty, and a reduced quality of life.

Modern rehabilitation therefore looks beyond restoring motor function alone. It also addresses cerebral perfusion, oxidative stress, inflammation, and the brain's own capacity for neuroplasticity.

Among the supportive rehabilitation techniques studied over recent decades is Intravenous Laser Blood Irradiation (ILBI), also known as VLOK — a method developed and most extensively studied in Eastern Europe and Russia.

What Is ILBI?

ILBI is a photobiomodulation technique in which low-level laser light is delivered directly into the bloodstream through a thin optical fiber inserted into a peripheral vein.

Unlike surgical or ablative lasers, ILBI uses extremely low power — typically 1.5–2 mW — and does not heat or damage tissue. The objective is not local tissue destruction, but a systemic biological response.

Proposed Mechanisms of Action

Experimental and clinical research describes several biological effects associated with ILBI.

Blood Rheology

ILBI has been studied for its potential to improve erythrocyte deformability, reduce platelet aggregation, decrease blood viscosity, and enhance microcirculation — changes that may improve oxygen delivery to ischemic tissue [1].

Endothelial Function

Photobiomodulation appears to stimulate endothelial nitric oxide release, promoting vasodilation and supporting regional perfusion.

Anti-Inflammatory Effects

Several studies report reductions in inflammatory mediators and oxidative stress markers following ILBI.

Immune Modulation

Low-level laser therapy has been studied for its potential to help normalize immune responses without causing immunosuppression.

Cellular Energy Production

Laser light absorbed by mitochondrial chromophores is understood to increase ATP synthesis — potentially supporting cellular recovery after ischemic injury [2].

Clinical Use After Ischemic Stroke

Published clinical studies, largely from Russia, describe ILBI as an adjunctive therapy used during stroke rehabilitation [1]. Reported areas of improvement include headache, dizziness, tinnitus, autonomic dysfunction, blood pressure stability, fatigue, and overall neurological recovery.

Some studies describe clinical improvement becoming noticeable after the second or third treatment session, with the greatest reported benefit in patients treated during the first year after an ischemic stroke. As with the mechanisms above, this evidence should be read as a description of what has been reported in the published literature to date, not as a guarantee of individual outcomes.

Typical Treatment Protocol

A commonly described protocol includes:

| Parameter | Value |

| Wavelength | 635 nm |

| Power | 1.5–2.0 mW |

| Session duration | 15–20 minutes |

| Frequency | Daily |

| Total sessions | 8–12 |

Some protocols combine ILBI with ultraviolet blood irradiation or transcutaneous laser therapy, depending on the patient's clinical picture.

Safety

Published clinical experience indicates that ILBI is generally well tolerated when performed by trained professionals using certified medical devices. Reported adverse effects are uncommon and usually mild. Standard contraindications for intravenous procedures and laser therapy should always be respected, and ILBI should only be performed following a physician's clinical assessment.

Current Evidence — Read Carefully

Most published clinical research on ILBI originates from Russia and Eastern Europe. Several studies report improvements in neurological symptoms, cerebral circulation, and rehabilitation outcomes. However, large multicenter randomized controlled trials conducted to current international standards remain limited.

For this reason, ILBI should currently be considered an adjunctive rehabilitation technique — not a replacement for evidence-based stroke treatment, including thrombolysis, thrombectomy, antithrombotic therapy, blood pressure control, and structured neurorehabilitation, as defined by international stroke care guidelines [3][4].

ILBI at EuroMed

At EuroMed, ILBI is delivered through our certified LASMIK system, always as a supportive addition to — never a substitute for — a patient's standard, evidence-based stroke care and rehabilitation plan.

Candidacy is assessed individually: our physicians review each patient's neurological status, stroke history, and existing treatment plan before recommending ILBI as part of a coordinated rehabilitation program, delivered under direct medical supervision.

Conclusion

Intravenous Laser Blood Irradiation represents a promising supportive modality in stroke rehabilitation. By supporting microcirculation, modulating inflammation, and supporting cellular metabolism, ILBI may contribute to functional recovery and quality of life in selected patients, alongside standard care.

Further high-quality international clinical studies are needed to fully define its role within modern stroke rehabilitation [5].

---

ILBI is available at EuroMed in Tijuana as part of a physician-directed stroke rehabilitation plan. To learn more or to discuss whether ILBI may be appropriate for your recovery, speak with your EuroMed concierge coordinator.

---

Sources

[1] Moskvin S.V., Kochetkov A.V. "Russian low level laser therapy techniques for brain disorders." In: Hamblin MR, Huang Y-Y (eds.), Photobiomodulation in the Brain: Low-Level Laser (Light) Therapy in Neurology and Neuroscience. Academic Press/Elsevier, 2019, pp. 545–572. DOI: 10.1016/B978-0-12-815305-5.00040-3.

[2] Hamblin M.R. "Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation." Photochemistry and Photobiology, 2018;94(2):199–212. PMID 29164625.

[3] World Stroke Organization. "Global Stroke Services Guidelines and Action Plan." International Journal of Stroke, 2014. PMID 25250836. world-stroke.org.

[4] American Heart Association/American Stroke Association. "Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update." Stroke, 2019. DOI 10.1161/STR.0000000000000211.

[5] World Association for Photobiomodulation Therapy (WALT), waltpbm.org.